Updates are available Correction dated 2024-09-13
Click to view Correction: https://doi.org/10.1038/s42003-024-06863-6
-
Authors
Moule, Madeleine G. https://orcid.org/0000-0002-9612-4563
Benjamin, Aaron B.
Burger, Melanie L.
Herlan, Claudine
Lebedev, Maxim
Lin, Jennifer S.
Koster, Kent J.
Wavare, Neha
Adams, Leslie G. https://orcid.org/0000-0002-7246-1602
Bräse, Stefan
Munoz-Medina, Ricardo
Cannon, Carolyn L.
Barron, Annelise E. https://orcid.org/0000-0002-0735-6873
Cirillo, Jeffrey D. https://orcid.org/0000-0003-3058-2702
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI149383, EB032983, OD029517)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 13 August 2024
First Online: 22 August 2024
Change Date: 13 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-024-06863-6
Competing interests
: A.E.B. is a shareholder and former member of the Board of Directors of Maxwell Biosciences, Inc., which is developing the antimicrobial peptoids for clinical use. JDC is also a shareholder in Maxwell Biosciences Inc. No employee of Maxwell Biosciences had any role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
: All protocols were approved (IACUC 2021-0201 M) by the Texas A&M University Institutional Animal Care and Use Committee. All authors of this study have fulfilled the criteria for authorship required by Nature Portfolio journals and participated in the design and implementation of the study.
